Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
14.19
-0.41 (-2.81%)
At close: Sep 4, 2026, 4:00 PM EDT
14.18
-0.01 (-0.07%)
After-hours: Sep 4, 2026, 7:30 PM EDT
Atrium Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Atrium Therapeutics stock have an average target of $25, which predicts a 76.18% increase from the current stock price of 14.19.
Price Target: $25 (+76.18%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Atrium Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 3 | 3 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $25 | Buy | Maintains | $25 | +76.18% | Aug 14, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +76.18% | Aug 13, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $25 | Buy | Maintains | $25 | +76.18% | Aug 13, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $25 | Buy | Initiates | $25 | +76.18% | May 15, 2026 |
Financial Forecast
Revenue This Year
34.36M
from 18.62M
Increased by 84.55%
Revenue Next Year
2.00M
from 34.36M
Decreased by -94.18%
EPS This Year
-4.55
EPS Next Year
-8.06
from -4.55
EPS and Forward PE are based on non-GAAP adjusted numbers.